1. Home
  2. ELTK vs EQ Comparison

ELTK vs EQ Comparison

Compare ELTK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELTK
  • EQ
  • Stock Information
  • Founded
  • ELTK 1970
  • EQ 2017
  • Country
  • ELTK Israel
  • EQ United States
  • Employees
  • ELTK N/A
  • EQ N/A
  • Industry
  • ELTK Electrical Products
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELTK Technology
  • EQ Health Care
  • Exchange
  • ELTK Nasdaq
  • EQ Nasdaq
  • Market Cap
  • ELTK 68.1M
  • EQ 67.9M
  • IPO Year
  • ELTK 1997
  • EQ 2018
  • Fundamental
  • Price
  • ELTK $10.28
  • EQ $1.61
  • Analyst Decision
  • ELTK
  • EQ Hold
  • Analyst Count
  • ELTK 0
  • EQ 2
  • Target Price
  • ELTK N/A
  • EQ $1.00
  • AVG Volume (30 Days)
  • ELTK 7.7K
  • EQ 2.6M
  • Earning Date
  • ELTK 08-14-2025
  • EQ 11-12-2025
  • Dividend Yield
  • ELTK 1.85%
  • EQ N/A
  • EPS Growth
  • ELTK N/A
  • EQ N/A
  • EPS
  • ELTK 0.45
  • EQ N/A
  • Revenue
  • ELTK $49,563,000.00
  • EQ $16,553,000.00
  • Revenue This Year
  • ELTK $18.60
  • EQ N/A
  • Revenue Next Year
  • ELTK $9.04
  • EQ N/A
  • P/E Ratio
  • ELTK $22.71
  • EQ N/A
  • Revenue Growth
  • ELTK 6.75
  • EQ N/A
  • 52 Week Low
  • ELTK $7.65
  • EQ $0.27
  • 52 Week High
  • ELTK $12.19
  • EQ $2.35
  • Technical
  • Relative Strength Index (RSI)
  • ELTK 53.52
  • EQ 52.54
  • Support Level
  • ELTK $9.90
  • EQ $1.59
  • Resistance Level
  • ELTK $10.25
  • EQ $2.02
  • Average True Range (ATR)
  • ELTK 0.20
  • EQ 0.26
  • MACD
  • ELTK 0.02
  • EQ -0.07
  • Stochastic Oscillator
  • ELTK 75.00
  • EQ 11.76

About ELTK Eltek Ltd.

Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: